Stem Cell Banking Market size is anticipated to cross USD 34.28 billion by the end of 2035, growing at a CAGR of 11.20% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of stem cell banking was over USD 9.59 billion. The growth of the market can be attributed to growing investment in stem cell research by number of nations owing to stem cell capacity to completely transform the way diseases are treated in people. The Novo Nordisk Foundation was anticipated to contribute up to USD 340 million over ten years to the creation of a worldwide stem cell research facility in 2022. Moreover, stem cell is a complex and continuous to conduct research on. Therefore, this factor is also anticipated to boost the investment on stem cell research.
Moreover, there has been growing need for stem cell transplant all across the world. Around 12 lakh transplants have been performed utilizing stem cells globally during the past 50 years. Presently, there are more than 49,000 transplants performed annually, and the number is rising. However, stem cells still need to be kept in reserve for potential autologous or allogeneic applications, even when they are employed for medical treatments. Through using this method, less human tissues would be used, and more studies could be compared. Hence, stem cell banks have been set up for both current research and therapy, raising some ethical, legal, and social concerns in the process. Hence, owing to this stem cell banking market is estimated to grow.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
11.20% |
|
Base Year Market Size (2022) |
USD 9.59 Billion |
|
Forecast Year Market Size (2035) |
USD 34.28 Billion |
|
Regional Scope |
|
Cell Type (Umbilical Cord Stem Cell, Cord Blood, Cord Tissue, Placenta, Adult Stem Cell, Embryonic Stem Cell)
The global stem cell banking market is segmented and analyzed for demand and supply by cell type into umbilical cord stem cell, cord blood, cord tissue, placenta, adult stem cell, and embryonic stem cell. Out of which, the cord blood segment is anticipated to garner the highest revenue by the end of 2035. The growth of the segment can be attributed to the growing registration of cord blood donor. There were more than 265,000 cord blood units registered as donors in United States. More than 114,000 units from the National Cord Blood Inventory (NCBI) was included in this figure, and more than 3,000 NCBI units was estimated to be added in 2021. Moreover, umbilical cord blood is also used to extract stem cells for transplantation. The blood that remains in an umbilical cord after a baby is born is known as umbilical cord blood. Until, it is utilized in a cord blood transplant, the cord blood is frozen and kept in storage. Compared to other bone marrow transplant choices, cord blood has fewer stem cell options. Yet, compared to bone marrow stem cells, those found in cord blood have a greater capacity to proliferate blood cells. Since, cord blood cells have not been exposed to pathogens, they are also immunologically immature. This increases their tolerance for tissue mismatches between the patient's and the lead cells. Patients who are in need of transplants however lack a fully matched donor could use them. Hence, owing to this the segment is estimated to grow.
Bank Type (Public, Private)
The global stem cell banking market is also segmented and analyzed for demand and supply by bank type into public and private. Amongst which, the private segment is anticipated to have the significant growth over the forecast period. An individual or family may store their stem cells in private banking for later use. Moreover, in the event that a family member is later identified as having an illness that could be treated with stem cells, this kind of bank provides a form of health insurance to each family. Hence, this bank is known for providing premium services which would drive the growth of the segment. Additionally, the American Academy of Pediatrics (AAP) recommends to only take private lead banking into account if a family member suffers from a hereditary illness that could be helped by stem cell therapies. The reason for this is that a non-family donation may not be a good match for the sick member of the family, whereas cord blood from the kid might.
Our in-depth analysis of the global stem cell banking market includes the following segments:
|
By Service Type |
|
|
By Utilization |
|
|
By Cell Type |
|
|
By Bank Type |
|
North American Market Forecast
The share of stem cell banking market in North America, amongst the market in all the other regions, is projected to have the highest growth, backed by growing prevalence of chronic disease, along with well-established medical infrastructure. Six in ten Americans have at least one chronic illness, such as diabetes, cancer, heart disease, and stroke. The top causes of death and disability in America are these and other chronic disorders. Moreover, genetic problems, other reproduction-related disorders, and infertility are on rise in this region. These together have a significant negative influence on the mental wellbeing of those who experience it, which lowers their quality of life. Hence, the need for stem cell banking in this region is estimated to boost. Additionally, with more research and development operations in the healthcare sector, this could also be ascribed to the sector's expanding developments. The stem cell banking market is also expanding as a result of the increased initiatives being taken by different research institutes and organizations to improve medical facilities and services.
APAC Market Statistics
The Asia Pacific stem cell banking market is estimated to be the second largest, to have the highest growth. The growth of the market in this region can be attributed to growing adoption of medical advancement such as stem cell treatment. For instance, India is one of the top international destinations for medical tourism. India is a pioneer in embracing medical breakthroughs. The top stem cell experts work for them. When compared to other nations, the price of stem cell therapy is also much lower in India. Therefore, the growth in India could boost the overall growth of Asia Pacific region. Moreover, the increased incidence of chronic illnesses such as cancer, diabetes, and cardiovascular disorders as well as the region's ageing population are to blame for the region's increasing demand for stem cell therapy, further boosting market growth. Future stem cell banking market expansion in this region is also anticipated to be aided by increased stem cell research initiatives, collaborations between academics and industry, and public understanding of the therapeutic advantages of stem cell therapy.
Europe Market Forecast
Additionally, the stem cell banking market in Europe region is also expected to have significant growth over the forecast period, backed by presence of top key players in this region. Also, there has been growing development of advanced storage devices in order to store stem cell in the banking services. Moreover, Ireland, Sweden, Finland, Belgium, Greece, Britain, Denmark, and the Netherlands are among the European Union nations that allow stem cell research involving human embryos, when it is banned from most of the top growing countries in this field.
As a partner stem cell bank, Smart Cells International Ltd collaborates with the charity Leukaemia & Myeloma Research UK (LMRUK). By participating in this agreement, qualified pregnant moms would have the option to freeze their baby's umbilical cord blood stem cells at the time of birth in case they are later required to treat the child or a sibling if they are a good match.
The Brazilian Patent Office has approved the patent application titled, "A method of generating cells which secrete Brain Derived Neurotrophic Factor (BDNF), Glial Derived Neurotrophic Factor (GDNF), Hepatocyte Growth Factor (HGF), and Vascular Endothelial Growth Factor (VEGF), wherein said cells do not secrete Nerve Growth Factor," according to Brainstorm Cell Limited a leading provider of adult stem cell therapeutics for neurode (NGF). The approved claims include a process for producing MSC-NTF cells (NurOwn).
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?